Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 134

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 134
---
, or will otherwise be in compliance with other Nasdaq listing criteria, including remaining in compliance with the minimum bid price requirement. If the Nasdaq Capital Market delists Cara’s securities from trading on its exchange for failure to meet the listing standards, Cara and its stockholders could face significant negative consequences including: reducing the liquidity and market price of its common stock; reducing the number of investors willing to hold or acquire its common stock, which could negatively impact Cara’s ability to raise equity financing; decreasing the amount of news and analyst coverage of Cara; and limiting Cara’s ability to issue additional securities or obtain additional financing in the future. In addition, delisting from Nasdaq may negatively impact Cara’s reputation and, consequently, its business. The market price of Cara’s common stock has been, and is likely to continue to be, highly volatile, and you may not be able to resell your shares at or above the price you paid for them. Since Cara’s initial public offering in January 2014, Cara’s stock price has been volatile and it is likely that the trading price of its common stock will continue to be volatile. As a result of this volatility, investors may not be able to sell their common stock at or above the price paid for the shares. The market price for Cara’s common stock may be influenced by many factors, including:

| ● | the outcome of Cara’s exploration of strategic alternatives; |

| ● | actual or anticipated variations in quarterly or annual operating results; |

| ● | failure to meet or exceed financial projections Cara provides to the public; |

| ● | failure to meet or exceed the estimates and projections of the investment community, including securities analysts; |

| ● | announcements by Cara or Cara’s competitors of significant acquisitions, strategic partnerships, or divestitures; |

| ● | introduction of competitive products or technologies; |

| ● | the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; |

| ● | general trends in Cara’s industry or economic and market conditions and overall fluctuations in U.S. equity markets; |

| ● | developments concerning Cara’s sources of manufacturing supply, warehousing and inventory control; |

| ● | disputes or other developments relating to patents or other proprietary rights; |

| ● | additions or departures of key scientific or management personnel; |

| ● | announcements of investigations or regulatory scrutiny of Cara’s operations or lawsuits filed against it; |

| ● | capital commitments; |

| ● | investors’ general perception of the company and its business;